
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab is a promising investment opportunity with a positive outlook due to its strong partnership with Johnson & Johnson for DARZALEX, a leading product in the multiple myeloma market. The company also has a diverse pipeline with promising candidates targeting different oncologic indications, which could drive future growth. However, risks include potential challenges in obtaining label extensions and competition from other agents in clinical testing.
Bears say
Genmab is showing signs of strong financial performance with net earnings exceeding expectations and a solid cash balance of ~$2.9B. However, the negative outlook is due to concerns about the company's future pipeline and potential market saturation for its leading product, DARZALEX, which accounted for a majority of the company's revenue in 2025. Additionally, increased competition in the biotech sector and potential for clinical trial setbacks could impact the company's profitability and valuation.
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares